Skip to content

Observation study on the efficacy of Baduanjin combined with moxa box moxibustion in improving gastrointestinal dysfunction in the elderly

Observation study on the efficacy of Baduanjin combined with moxa box moxibustion in improving gastrointestinal dysfunction in the elderly

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000167
Enrollment
Unknown
Registered
2025-01-25
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal dysfunction in the elderly

Interventions

Experimental group:On the basis of conventional treatment (such as moxapride montmorillonite powder sulcoaluminum suspension etc.) Baduanjin combined with moxibustion box was used
control group:Conventional treatments (such as mosapride montmorillonite powder sucralfate suspension etc.)

Sponsors

Guangdong Provincial Hospital of traditional Chinese medicine (emergency department)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1) Age = 60 = 85 years old regardless of gender. 2) Those who meet the diagnosis of gastrointestinal dysfunction in multiple organ dysfunction syndrome (disease staging diagnosis and severity scoring criteria). 3) It meets the relevant TCM diagnostic criteria of "deficiency of Qi and blood in spleen and stomach". 4) Sign informed consent and participate in clinical research.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1) Patients with malignant tumor severe liver and kidney dysfunction and hematological diseases. 2) Allergic to the ingredients of moxa sticks or intolerant to moxa box moxibustion. 3) The patients with difficulty in standing or falling score were at medium and high risk. 4) Failure to cooperate with the treatment as required during the treatment process which affects the judgment of curative effect. 5) Those who have participated in other clinical trials in recent 3 months.

Design outcomes

Primary

MeasureTime frame
clinical efficacy;Gastrointestinal Symptom Rating Scale;

Secondary

MeasureTime frame
changes in abdominal circumference;bowel sounds;frequency of bowel movements per day and stool morphology;

Countries

China

Contacts

Public ContactJing Zhu

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

zj2858@126.com13760655628

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026